ADAM17

ADAM17 Molekülinformation

Englischer Name	Disintegrin and metalloproteinase domain-containing protein 17	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2	Target-Alias	EC:3.4.24.86，ADAM17 Protein，ADAM 17，Snake venom-like protease，CSVP，CD156b，ADAM17，ADAM Metallopeptidase Domain 17，TNF-Alpha Convertase，TACE，TNF-Alpha Converting Enzyme，TNF-Alpha-Converting Enzyme，CD156b Antigen，EC 3.4.24.86，NISBD1，NISBD，Disintegrin and metalloproteinase domain-containing protein 17，Tumor Necrosis Factor， Alpha， Converting Enzyme，ADAM Metallopeptidase Domain 18，ADAM18
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	Disintegrin and metalloproteinase domain-containing protein 17
Target-Alias	EC:3.4.24.86，ADAM17 Protein，ADAM 17，Snake venom-like protease，CSVP，CD156b，ADAM17，ADAM Metallopeptidase Domain 17，TNF-Alpha Convertase，TACE，TNF-Alpha Converting Enzyme，TNF-Alpha-Converting Enzyme，CD156b Antigen，EC 3.4.24.86，NISBD1，NISBD，Disintegrin and metalloproteinase domain-containing protein 17，Tumor Necrosis Factor， Alpha， Converting Enzyme，ADAM Metallopeptidase Domain 18，ADAM18
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

ADAM17 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Mouse (1)Human (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
AD7-H53H3	Human	CHO	Human ADAM17 / TACE / CD156b Protein, His Tag (active enzyme)				In den Warenkorb legen
AD7-M52H1	Mouse	HEK293	Mouse ADAM17 / TACE / CD156b Protein, His Tag				In den Warenkorb legen

Gesamtmenge2

ADAM17 Molekülhintergrund

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

ADAM17 Molekülalias

ADAM17,TACE,CD156b

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Aderbasib	INCB-7839; INC-B007839; INCB-007839	Phase 1 Clinical	Incyte Corp	Astrocytoma; Breast Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Glioma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Oligodendroglioma; Solid tumours	Details
ORYN-1001	ORTD-1; ORYN-1001	Phase 1 Clinical	Oryn Therapeutics Llc	Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)	Details